Biomarker detection and validation challenges
AI-driven precision medicine in oncology.
Commercial assays for biomarker detection frequently utilize different reagents which each manufacturer considers proprietary. Subsequently, results may not match from vendor to vendor. Read how one group performed their own internal validation studies to address these concerns and effectively measure IL-6 and sIL-6R in patients following CAR T cell therapy.
Click here to access the full article on PubMed.
